MTSL yields 59.35% · PFE yields 6.13%● Live data
📍 MTSL pulled ahead of the other in Year 1
Combined, MTSL + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MTSL + PFE for your $10,000?
MER Telemanagement Solutions Ltd. engages in the provision of expense management and billing solutions and services. The firm is provider of solutions for online video advertising and telecommunications expense management (TEM) used by enterprises, and billing solutions used by information and telecommunication service providers. The firm operates through three segments: Enterprise, Service Providers and Video Advertising. Its Enterprise segment includes TEM solutions and services. Its Service Providers segment includes billing, mobile virtual network operator (MVNO) and machine-to-machine/Internet of Things (IoT/M2M) services and solutions. The online video advertising is provided through Vexigo Ltd. (Vexigo), a subsidiary of the Company, which has an in-house technology solution designed for content publishers. The Vexigo solution for online and mobile platforms supports multiple advertisement formats and interactive advertisement units.
Full MTSL Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.